Company Reports Q1 Revenue of $26.5M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Reports Q1 revenue $26.5M, consensus $26.09M. "Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring platform," said co-founder and CEO Jane Chao, Ph.D. "The launch of our neonate and pediatric offerings represents a major milestone in our commitment to provide critical brain monitoring for patients of all ages. As we work to redefine the standard of care in seizure management, we will continue to invest in innovation and expansion of our clinical indications to advance our mission to make EEG a new vital sign."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBLL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBLL
Wall Street analysts forecast CBLL stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.670
Low
29.00
Averages
29.67
High
30.00
Current: 18.670
Low
29.00
Averages
29.67
High
30.00
About CBLL
CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its hardware is composed of disposable, flexible headbands and head caps (Wearables) and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals. EEG data captured by the recorder are interpreted by its proprietary AI-powered seizure detection algorithms, which monitor the patient’s EEG signal and support the clinician’s real-time assessment of seizure activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CeriBell Reports Strong Q1 2026 Earnings with Revenue Growth and Strategic Launches
- Significant Revenue Growth: CeriBell achieved $26.5 million in revenue for Q1 2026, reflecting a 29% year-over-year increase and a 7% sequential rise, primarily driven by record headband utilization and an increase in net new accounts, indicating strong market performance.
- Stable Gross Margin: The gross margin for Q1 stood at 87%, achieved despite high tariffs on inventory sourced from China, with the company nearly fully offsetting these costs through various cost reduction initiatives, and it expects to maintain margins in the high 80% range throughout 2026, bolstering investor confidence.
- Strong Hospital Account Growth: By the end of Q1, CeriBell had 680 active hospitals using its system, with 33 net new accounts added, marking the strongest single quarter of account growth since going public, demonstrating sustained market demand.
- Strategic Product Launches: The company initiated the full commercial launch of its neonate and pediatric products in Q1 and activated its first delirium monitoring pilot site in April, which is expected to provide significant revenue growth drivers in the future, alongside a supportive CMS proposed rule for up to $2,171 in incremental reimbursement per patient.
See More
CeriBell, Inc. Reports Strong Q4 2025 Earnings and Market Expansion
- Significant Revenue Growth: CeriBell reported fourth-quarter revenue of $24.8 million, a 34% increase year-over-year, with full-year revenue reaching $89.1 million, reflecting a 36% growth that underscores the company's strong performance in its core seizure market and market penetration capabilities.
- Market Expansion Strategy: The total addressable market has expanded from $2 billion to $3.5 billion, primarily due to FDA clearance for seizure detection in neonate and pediatric patients, which is expected to unlock approximately $400 million in market opportunities for the company.
- Account Growth and Infrastructure Enhancement: By the end of 2025, CeriBell increased its active accounts to 647, adding 32 new accounts, while expanding its commercial infrastructure from 35 to 55 territories, thereby enhancing its competitive position in new markets.
- Optimistic 2026 Outlook: The company anticipates total revenue for 2026 to be between $111 million and $115 million, representing a 25% to 29% annual growth, and plans to fully launch its neonate and pediatric products in Q2, although initial revenue contributions are expected to be modest, indicating significant long-term growth potential.
See More
CeriBell Reports 2025 Financials and 2026 Outlook
- Significant Revenue Growth: CeriBell reported total revenue of $24.78 million for Q4 2025, a 34% increase driven by expansion into new accounts and continued growth within its active account base, indicating strong demand in the medical technology market.
- Widened Net Loss: The net loss for Q4 2025 widened to $13.53 million; however, the loss per share narrowed from $0.40 to $0.36, suggesting progress in controlling per-share losses, which may enhance investor confidence.
- Optimistic Future Outlook: CeriBell expects full-year revenue for 2026 to be between $111 million and $115 million, representing a growth of approximately 25% to 29% from 2025, reflecting the company's positive expectations regarding market demand and product potential.
- FDA Approvals for New Technologies: CeriBell's Clarity algorithm and proprietary delirium monitoring solution received FDA 510(k) clearance, marking significant technological innovation in neuro-monitoring that could strongly support future market expansion.
See More
CeriBell Q4 Earnings Exceed Expectations
- Earnings Highlights: CeriBell reported a Q4 GAAP EPS of -$0.36, beating market expectations by $0.05, indicating positive signs in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $24.8 million, a 33.8% year-over-year increase, surpassing expectations by $0.85 million, reflecting strong demand for its products and an increase in market share.
- Investor Conferences: CeriBell presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the healthcare sector and attracting potential investor interest.
- Market Ratings: Seeking Alpha's quant rating on CeriBell indicates market recognition of its future growth potential, which may draw more investor attention to its stock performance.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
- Market Growth Potential: The AI medical imaging market is projected to grow at an annual rate of 25.8% through 2034, driving a shift in healthcare from traditional hardware to agile, software-defined intelligence, creating significant opportunities for companies like VentriPoint.
- Successful Funding: VentriPoint doubled its private placement from $500,000 to $1 million, with proceeds earmarked for critical commercialization activities and manufacturing scale-up, ensuring the company maintains a competitive edge in the rapidly evolving market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby enhancing market competitiveness and driving customer adoption.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, bringing over 15 years of management experience in the medical technology sector, which is viewed as a key step in executing strategies to drive market adoption and revenue growth.
See More
CeriBell (CBLL) Receives FDA Breakthrough Device Designation for Stroke Detection Monitor
- Breakthrough Device Certification: CeriBell's stroke monitoring device has received FDA Breakthrough Device Designation, utilizing existing EEG technology and an AI-driven algorithm to significantly enhance the detection speed of Large Vessel Occlusion strokes in hospitals, which is expected to improve patient outcomes.
- Technological Innovation: This device is the first of its kind to combine EEG technology with an AI-driven algorithm, enabling rapid stroke identification that helps hospitals reduce diagnostic time, thereby increasing patient survival rates and recovery quality.
- Market Prospects: CeriBell has also recently received FDA approvals for its technologies aimed at detecting seizures and monitoring delirium, indicating the company's ongoing innovation capabilities in the neuro-monitoring field, which may lay the groundwork for future market expansion.
- Stock Price Reaction: CBLL shares rose 3.12% to $21.97 in Nasdaq trading, reflecting positive market sentiment towards this breakthrough technology, which could enhance investor confidence and drive future company growth.
See More
CeriBell Reports Strong Q1 2026 Earnings with Revenue Growth and Strategic Launches
- Significant Revenue Growth: CeriBell achieved $26.5 million in revenue for Q1 2026, reflecting a 29% year-over-year increase and a 7% sequential rise, primarily driven by record headband utilization and an increase in net new accounts, indicating strong market performance.
- Stable Gross Margin: The gross margin for Q1 stood at 87%, achieved despite high tariffs on inventory sourced from China, with the company nearly fully offsetting these costs through various cost reduction initiatives, and it expects to maintain margins in the high 80% range throughout 2026, bolstering investor confidence.
- Strong Hospital Account Growth: By the end of Q1, CeriBell had 680 active hospitals using its system, with 33 net new accounts added, marking the strongest single quarter of account growth since going public, demonstrating sustained market demand.
- Strategic Product Launches: The company initiated the full commercial launch of its neonate and pediatric products in Q1 and activated its first delirium monitoring pilot site in April, which is expected to provide significant revenue growth drivers in the future, alongside a supportive CMS proposed rule for up to $2,171 in incremental reimbursement per patient.
See More
CeriBell, Inc. Reports Strong Q4 2025 Earnings and Market Expansion
- Significant Revenue Growth: CeriBell reported fourth-quarter revenue of $24.8 million, a 34% increase year-over-year, with full-year revenue reaching $89.1 million, reflecting a 36% growth that underscores the company's strong performance in its core seizure market and market penetration capabilities.
- Market Expansion Strategy: The total addressable market has expanded from $2 billion to $3.5 billion, primarily due to FDA clearance for seizure detection in neonate and pediatric patients, which is expected to unlock approximately $400 million in market opportunities for the company.
- Account Growth and Infrastructure Enhancement: By the end of 2025, CeriBell increased its active accounts to 647, adding 32 new accounts, while expanding its commercial infrastructure from 35 to 55 territories, thereby enhancing its competitive position in new markets.
- Optimistic 2026 Outlook: The company anticipates total revenue for 2026 to be between $111 million and $115 million, representing a 25% to 29% annual growth, and plans to fully launch its neonate and pediatric products in Q2, although initial revenue contributions are expected to be modest, indicating significant long-term growth potential.
See More
CeriBell Reports 2025 Financials and 2026 Outlook
- Significant Revenue Growth: CeriBell reported total revenue of $24.78 million for Q4 2025, a 34% increase driven by expansion into new accounts and continued growth within its active account base, indicating strong demand in the medical technology market.
- Widened Net Loss: The net loss for Q4 2025 widened to $13.53 million; however, the loss per share narrowed from $0.40 to $0.36, suggesting progress in controlling per-share losses, which may enhance investor confidence.
- Optimistic Future Outlook: CeriBell expects full-year revenue for 2026 to be between $111 million and $115 million, representing a growth of approximately 25% to 29% from 2025, reflecting the company's positive expectations regarding market demand and product potential.
- FDA Approvals for New Technologies: CeriBell's Clarity algorithm and proprietary delirium monitoring solution received FDA 510(k) clearance, marking significant technological innovation in neuro-monitoring that could strongly support future market expansion.
See More
CeriBell Q4 Earnings Exceed Expectations
- Earnings Highlights: CeriBell reported a Q4 GAAP EPS of -$0.36, beating market expectations by $0.05, indicating positive signs in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $24.8 million, a 33.8% year-over-year increase, surpassing expectations by $0.85 million, reflecting strong demand for its products and an increase in market share.
- Investor Conferences: CeriBell presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the healthcare sector and attracting potential investor interest.
- Market Ratings: Seeking Alpha's quant rating on CeriBell indicates market recognition of its future growth potential, which may draw more investor attention to its stock performance.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
- Market Growth Potential: The AI medical imaging market is projected to grow at an annual rate of 25.8% through 2034, driving a shift in healthcare from traditional hardware to agile, software-defined intelligence, creating significant opportunities for companies like VentriPoint.
- Successful Funding: VentriPoint doubled its private placement from $500,000 to $1 million, with proceeds earmarked for critical commercialization activities and manufacturing scale-up, ensuring the company maintains a competitive edge in the rapidly evolving market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby enhancing market competitiveness and driving customer adoption.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, bringing over 15 years of management experience in the medical technology sector, which is viewed as a key step in executing strategies to drive market adoption and revenue growth.
See More
CeriBell (CBLL) Receives FDA Breakthrough Device Designation for Stroke Detection Monitor
- Breakthrough Device Certification: CeriBell's stroke monitoring device has received FDA Breakthrough Device Designation, utilizing existing EEG technology and an AI-driven algorithm to significantly enhance the detection speed of Large Vessel Occlusion strokes in hospitals, which is expected to improve patient outcomes.
- Technological Innovation: This device is the first of its kind to combine EEG technology with an AI-driven algorithm, enabling rapid stroke identification that helps hospitals reduce diagnostic time, thereby increasing patient survival rates and recovery quality.
- Market Prospects: CeriBell has also recently received FDA approvals for its technologies aimed at detecting seizures and monitoring delirium, indicating the company's ongoing innovation capabilities in the neuro-monitoring field, which may lay the groundwork for future market expansion.
- Stock Price Reaction: CBLL shares rose 3.12% to $21.97 in Nasdaq trading, reflecting positive market sentiment towards this breakthrough technology, which could enhance investor confidence and drive future company growth.
See More
